Reagan-Udall Post-Market Drug Surveillance Initiative Could Address Patient Web Sites
This article was originally published in The Pink Sheet Daily
Executive Summary
The IMEDS project getting under way at the Reagan-Udall Foundation could eventually address methods for analyzing data on drug side effects that are available through patient networking sites and blogs, though initial efforts will focus on insurance claims data and electronic medical records.
You may also be interested in...
US FDA Taps Pfizer Executive For CDER Deputy Director Slot
Patrizia Cavazzoni, Janet Woodcock's new #2, has a background similar to Richard Moscicki, CDER's previous deputy director for operations.
Medicare And Alzheimer’s Drugs: Recent NCDs Mainly Omit Research Requirement, Biogen Notes
Biogen suggests potential precedents in past coverage decisions for upcoming Medicare determination on Aduhelm and other amyloid-directed monoclonal antibodies during earnings call.
Semglee's Boost On Express Scripts Formulary Reflects Interchangeability – And Rebates
First interchangeable insulin biosimilar gains preferred status on one of the largest national formularies in the US.